Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app help keep your brain sharp? new study says maybe.

NCT ID NCT05565170

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a lifestyle program delivered through a smartphone app could help older adults (ages 60-77) at risk for dementia. 156 participants in four countries were split into two groups: one received a structured program with app support and in-person sessions, while the other got basic health advice. The main goal was to see if the program was practical and if it could lower dementia risk scores.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

156 people

The number who actually took part.

Started

Jan 2023

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 77 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 60-77 years * Cardiovascular Risk Factors, Aging and Incidence of Dementia (CAIDE) Risk Score ≥ 6 points * Cognitive performance at the mean level or slightly lower than expected for age, assessed with Mini-Mental State Examination (MMSE) and the Consortium to Establish a registry for Alzheimer's Disease (CERAD) verbal learning test (word list learning/recall) * Proficiency in the local language (German, Italian, Finnish or Swedish) * Ability and willingness to use an Android smartphone, access to and ability to use the internet (digital readiness) * Existing compatible smartphone (Android) or willingness to use a new Android smartphone provided from the study Exclusion Criteria: * Dementia or substantial cognitive impairment (e.g., memory clinic referral needed as judged by the study physician) * Current or past use of medications for Alzheimer's disease or related diseases (e.g., cholinesterase inhibitors, memantine) * Diminished decision-making capacity, not capable of consenting or completing study assessments, based on clinical judgement * Other significant neurologic disease, including but not limited to Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma with persistent neurologic sequelae or known structural brain abnormalities * Any condition affecting safe engagement in the intervention, e.g., malignant disease, major depression, symptomatic cardiovascular disease, revascularisation within 1 year previously * Severe loss of vision, hearing, or communicative ability; conditions preventing cooperation as judged by the study physician * Concomitant participation in an interventional trial (unless this will not interfere with the LETHE trial based on study staff's judgement)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia Risk Reduction Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Finnish Institute for Health and Welfare

    Helsinki, Finland

  • Karolinska Institutet

    Stockholm, Sweden

  • Medical University of Vienna

    Vienna, Austria

  • University of Perugia

    Perugia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.